The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Corporate Minority - P2P | IPO

Market Cap


Stock Price


About Biogen IDEC

Biogen (NASDAQ: BIIB) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Biogen IDEC Headquarter Location

Cambridge, Massachusetts, 02138,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biogen IDEC

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biogen IDEC is included in 3 Expert Collections, including Fortune 500 Investor list.


Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Biogen IDEC Patents

Biogen IDEC has filed 552 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Autoimmune diseases
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Autoimmune diseases, Monoclonal antibodies, Cytokines, Biotechnology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Autoimmune diseases, Monoclonal antibodies, Cytokines, Biotechnology



Latest Biogen IDEC News

Biosimilars Market Size to Surpass US$ 66.2 Billion by 2030

Nov 18, 2021

Companies Covered LG Life Sciences, Synthon Pharmaceuticals, Inc., Novartis, Merck Serono, TevaPharmaceutical Industries Ltd., Celltrion, Biocon, GenentechHospira, Biogen idec, Inc. North America region is estimated to be the most opportunistic market during the forecast period. North America is characterized by the increased demand for the advanced and innovative healthcare products, increased consumer expenditure on healthcare, and active participation of the regulatory authorities to overlook the matters related to the preclinical trials and product launches in the market. FDA in US has recently approved around 20 biosimilar products. The rising popularity of the biosimilar drugs among the patients in the US is expected to propel the demand for the biosimilars in North America. The rising burden of various chronic diseases such as cardiovascular diseases, diabetes, cancer, and kidney failure amongst the global population is boosting the growth of the biosimilars market. The biosimilars provide treatment to various chronic diseases at affordable costs and hence it is gaining popularity among the global consumers.The rising prevalence of diabetes is another major driver that may boost the demand for the biosimilar drugs. According to the World Health Organization, diabetes is the major reason behind the blindness, kidney failure, stroke, and heart attacks. The availability of affordable biosimilar drugs for the treatment of such serious diseases is boosting the market growth. The complexities related to the manufacturing of the biosimilar drugs and huge capital investments are the major drawbacks that can restrict market growth. Moreover, lack of awareness regarding the availability of biosimilars among the population especially in the developing and underdeveloped regions are the potential factors that may hamper the market growth during the forecast period. Based on the product, the monoclonal antibodies segment was the dominant segment in 2020. The extensive usage of monoclonal antibodies in the treatment of variousdiseases such as cancer, rheumatoid arthritis, cardiovascular diseases, and multiple sclerosis. This segment accounts for over 25% of the market share. The higher effectiveness of the monoclonal antibodies in the treatment of the cancer and diabetes is expected to drive the segment growth further in the upcoming years. Based on the application, the oncology segment dominated the market in 2020. According to the International Agency for Research on Cancer, around 19.3 million new cancer cases and around 10 million cancer related deaths were reported in the year 2020, across the globe. Prevalence of breast cancer in the female population is surging, accounting for around 11.7% of the new cancer cases followed by the lungs cancer that accounted for 11.4% and colorectal cancer accounted for 10.0% in 2020. Hence, the growing demand for the biosimilar drugs for the treatment of cancer is boosting the segment growth. In 2020, Pfizer obtained the FDA approval for its Nyvepria, which is used for lowering the infection incidences.In May 2020, Fresenius Kabi acquired approval for its MSB11455, a pegfilgrastim biosimilar, from both the FDA and EMA. Drug approval is a major strategy adopted by the market players. The various other developmental strategies like acquisition, partnerships, mergers, and government policies fosters market growth and offers lucrative growth opportunities to the market players. Browse more Related Reports@ Segments Covered in the Report By Product Buy this Premium Research Report@ You can place an order or ask any questions, please feel free to contact at  | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

Biogen IDEC Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biogen IDEC Rank

  • When was Biogen IDEC founded?

    Biogen IDEC was founded in 1978.

  • Where is Biogen IDEC's headquarters?

    Biogen IDEC's headquarters is located at Cambridge.

  • What is Biogen IDEC's latest funding round?

    Biogen IDEC's latest funding round is Corporate Minority - P2P.

  • Who are the investors of Biogen IDEC?

    Investors of Biogen IDEC include Seaport Capital and SV Investment Partners.

  • Who are Biogen IDEC's competitors?

    Competitors of Biogen IDEC include Ionis Pharmaceuticals and 2 more.

You May Also Like


AbbVie (NYSE: ABBV) consists of scientists, researchers, communicators, manufacturing specialists, and regulatory professionals who seek to come up with new approaches to addressing today's health issues-from life-threatening illness to chronic conditions. The company focuses its R&D efforts and technology investments to pursue this goal.

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Octapharma Logo

Octapharma is a provider of health solutions and human protein manufacturer, developing and producing human proteins from human plasma and human cell lines.

Sumitovant Logo

Sumitovant is a biopharmaceutical group focused on improving drug development. The company offers a tech-enabled approach to drug discovery, development and commercialization.

Ferring Pharmaceuticals Logo
Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. Ferring Pharmaceuticals specializes in the areas of reproductive medicine and women’s health, urology and gastroenterology.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.